Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An update from Theratechnologies ( (TSE:TH) ) is now available.
On February 13, 2025, Theratechnologies announced the resumption of distribution for its product EGRIFTA SV® after receiving clearance from the U.S. FDA to release two newly manufactured batches. This development signifies a positive step for the company, potentially impacting its market presence positively, especially after recent drug shortages. The ongoing FDA review of the company’s Prior Approval Supplement is expected to conclude by April 18, 2025, with implications for future product availability.
More about Theratechnologies
Theratechnologies Inc. is a Canadian pharmaceutical company based in Montréal, Québec. The company specializes in the development and commercialization of innovative therapies, primarily focusing on treatments for people with HIV. Its key product is EGRIFTA SV® (tesamorelin for injection), used to treat excess abdominal fat in HIV-infected patients with lipodystrophy.
YTD Price Performance: 4.35%
Average Trading Volume: 120,677
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $88.16M
For detailed information about TH stock, go to TipRanks’ Stock Analysis page.
